Literature DB >> 12904083

Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30).

Venkatram R Atigadda1, Kimberly K Vines, Clinton J Grubbs, Donald L Hill, Samuel L Beenken, Kirby I Bland, Wayne J Brouillette, Donald D Muccio.   

Abstract

Retinoids that activate the nuclear retinoid X receptors (RXRs) display potential for chemoprevention of breast cancer. We previously reported that 9cUAB30 (1) is an RXR-selective retinoid. To explore its in vivo chemopreventive activity, multigram quantities of 1 were needed. Here, we describe a modified synthesis that yields up to 100 g of 1. We further demonstrate that 1 is very effective in the prevention of N-methyl-N-nitrosourea induced mammary cancers in rats without signs of toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904083     DOI: 10.1021/jm030095q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells.

Authors:  Nathan J Hansen; Rebecca C Wylie; Sharla M O Phipps; William K Love; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Int J Oncol       Date:  2007-03       Impact factor: 5.650

3.  Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2015-05-05       Impact factor: 6.261

Review 4.  A review of the molecular design and biological activities of RXR agonists.

Authors:  Nathalia Rodrigues de Almeida; Martin Conda-Sheridan
Journal:  Med Res Rev       Date:  2019-04-03       Impact factor: 12.944

5.  UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.

Authors:  Evan F Garner; Laura L Stafman; Adele P Williams; Jamie M Aye; Caroline Goolsby; Venkatram R Atigadda; Blake P Moore; Li Nan; Jerry E Stewart; Anita B Hjelmeland; Gregory K Friedman; Elizabeth A Beierle
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

6.  Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.

Authors:  Anil Desphande; Gang Xia; LeeAnn J Boerma; Kimberly K Vines; Venkatram R Atigadda; Susan Lobo-Ruppert; Clinton J Grubbs; Fariba L Moeinpour; Craig D Smith; Konstantin Christov; Wayne J Brouillette; Donald D Muccio
Journal:  Bioorg Med Chem       Date:  2013-12-01       Impact factor: 3.641

7.  The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.

Authors:  Chu-Fang Chou; Yu-Hua Hsieh; Clinton J Grubbs; Venkatram R Atigadda; James A Mobley; Reinhard Dummer; Donald D Muccio; Isao Eto; Craig A Elmets; W Timothy Garvey; Pi-Ling Chang
Journal:  J Dermatol Sci       Date:  2018-03-15       Impact factor: 4.563

8.  Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Authors:  Peter T Vedell; Yan Lu; Clinton J Grubbs; Yuxin Yin; Hui Jiang; Kirby I Bland; Donald D Muccio; Dusica Cvetkovic; Ming You; Ronald Lubet
Journal:  Mol Pharmacol       Date:  2013-01-04       Impact factor: 4.436

9.  A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.

Authors:  Adele P Williams; Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  J Surg Res       Date:  2018-03-26       Impact factor: 2.192

10.  Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.

Authors:  Venkatram R Atigadda; Gang Xia; Anil Deshpande; Lizhi Wu; Natalia Kedishvili; Craig D Smith; Helen Krontiras; Kirby I Bland; Clinton J Grubbs; Wayne J Brouillette; Donald D Muccio
Journal:  J Med Chem       Date:  2015-09-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.